Copyright
©The Author(s) 2005.
World J Gastroenterol. Jul 28, 2005; 11(28): 4344-4350
Published online Jul 28, 2005. doi: 10.3748/wjg.v11.i28.4344
Published online Jul 28, 2005. doi: 10.3748/wjg.v11.i28.4344
Group IA | Group IB | Group II | All patients | |
n = 13 (37%) | n = 12 (34%) | n = 10 (29%) | n = 35 (100%) | |
Median age (range) | 35 (21-48) | 34 (20-45) | 52 (42-68) | 38 (20-68) |
Male (%) | 9 (69) | 11 (92) | 10 (100) | 30 (86) |
Chinese ethnicity (%) | 13 (100) | 11 (92) | 10 (100) | 34 (97) |
Median (range) baseline ALT, U/L | 28 (16-58) | 136 (78-1 124) | 87 (33-761) | 74(16-1 124) |
Median (range) baseline HBV DNA, Meg/mL | 294 (120–1 680) | 253 (38–616) | 291 (20–786) | 280 (20–1 680) |
Median baseline CPT score | NA | NA | 7.0 (5-13) | NA |
Median (range) duration of lamivudine | ||||
at emergence of genotypic resistance, wk | 160 (35-198) | 110 (42-212) | 62 (36-120) | 143 (35-212) |
Follow-up after genotypic resistance, wk | 96 (48-220) | 124 (26-208) | 64 (34-102) | 102 (26-220) |
Number (%) with phenotypic resistance | 3 (23) | 9 (75) | 6 (60) | 18 (51) |
Patients with phenotypic resistance n = 18 | Patients without phenotypic resistance n = 17 | P | |
Median (range) age (yr) | 34 (21-60) | 37(20-68) | 0.95 |
Male (%) | 17 (94) | 13 (76) | 0.16 |
Chinese (%) | 17/18 (94) | 17/17 (100) | 0.28 |
Genotype (B:C:others) | 7B/ 7C/ 2 others | 11B /6C/ 2 others | 0.56 |
Type of mutation (rtM204I:rtM204V:others) | 12:2:4 | 4:10:3 | 0.074 |
Median (range) baseline ALT level, U/L | 96 (42-1 124) | 40 (16-143) | 0.018 |
ALT level at emergence of genotypic resistance, U/L | 48 (22-82) | 36 (24-68) | 0.36 |
Successful HBeAg seroconversion (%) | 12 | 17.7 | 0.43 |
Median (range) baseline HBV DNA, Meq/mL | 249 (20-788) | 336 (20-1 680) | 0.17 |
Median (range) peak HBV DNA after emergence of resistance, pg/mL | 186 (8.8-1 064) | 314 (9-3 920) | 0.33 |
Median (range) duration of lamivudine at onset of resistance, wk | 88 (35-212) | 124 (36-202) | 0.16 |
Median (range) duration of follow up after resistance, wk | 124 (52-204) | 102 (26-220) | 0.29 |
Median (range) baseline CPT Score for cirrhotic patients, n = 10 | (n = 6) 8 (5-13) | (n = 4) 7 (5-9) | 0.038 |
- Citation: Dan YY, Wai CT, Lee YM, Sutedja DS, Seet BL, Lim SG. Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World J Gastroenterol 2005; 11(28): 4344-4350
- URL: https://www.wjgnet.com/1007-9327/full/v11/i28/4344.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i28.4344